| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
|
Weger, Vincent A. de
|
|
2017
|
81 |
1 |
p. 73-80
|
artikel
|
| 2 |
Advances in ovarian cancer therapy
|
Cortez, Alexander J.
|
|
2017
|
81 |
1 |
p. 17-38
|
artikel
|
| 3 |
A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer
|
Sakurai, Reiko
|
|
2017
|
81 |
1 |
p. 103-109
|
artikel
|
| 4 |
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia
|
Emadi, Ashkan
|
|
2017
|
81 |
1 |
p. 217-222
|
artikel
|
| 5 |
Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients
|
Andel, L. van
|
|
2017
|
81 |
1 |
p. 47
|
artikel
|
| 6 |
Correction to: Innovative intraoral cooling device better tolerated and equally effective as ice cooling
|
Walladbegi, Java
|
|
2017
|
81 |
1 |
p. 225
|
artikel
|
| 7 |
Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma
|
Badruddoja, Michael A.
|
|
2017
|
81 |
1 |
p. 223
|
artikel
|
| 8 |
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients
|
van Andel, L.
|
|
2017
|
81 |
1 |
p. 39-46
|
artikel
|
| 9 |
Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors
|
Lee, Lingaku
|
|
2017
|
81 |
1 |
p. 163-169
|
artikel
|
| 10 |
DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer
|
Nahid, Noor Ahmed
|
|
2017
|
81 |
1 |
p. 119-129
|
artikel
|
| 11 |
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review
|
Miyamoto, Morikazu
|
|
2017
|
81 |
1 |
p. 111-117
|
artikel
|
| 12 |
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects
|
Gerisch, Michael
|
|
2017
|
81 |
1 |
p. 195-206
|
artikel
|
| 13 |
Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment
|
Nikanjam, Mina
|
|
2017
|
81 |
1 |
p. 171-178
|
artikel
|
| 14 |
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
|
Jakobsen Falk, Ingrid
|
|
2017
|
81 |
1 |
p. 183-193
|
artikel
|
| 15 |
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
|
Jakobsen Falk, Ingrid
|
|
|
81 |
1 |
p. 183-193
|
artikel
|
| 16 |
Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats
|
Ito, Yukako
|
|
2017
|
81 |
1 |
p. 155-161
|
artikel
|
| 17 |
Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease
|
Krens, L. L.
|
|
2017
|
81 |
1 |
p. 179-182
|
artikel
|
| 18 |
Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer
|
Murakami, Shuji
|
|
2017
|
81 |
1 |
p. 81-87
|
artikel
|
| 19 |
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis
|
Schmid, Ulrike
|
|
2017
|
81 |
1 |
p. 89-101
|
artikel
|
| 20 |
Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)
|
Okuno, Kiyotaka
|
|
2017
|
81 |
1 |
p. 65-71
|
artikel
|
| 21 |
Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma
|
Altan, Bolag
|
|
2017
|
81 |
1 |
p. 141-153
|
artikel
|
| 22 |
The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats
|
Li, Nan
|
|
2017
|
81 |
1 |
p. 207-216
|
artikel
|
| 23 |
The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer
|
Masuda, Takeshi
|
|
2017
|
81 |
1 |
p. 131-139
|
artikel
|
| 24 |
The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer
|
Matherly, Larry H.
|
|
2017
|
81 |
1 |
p. 1-15
|
artikel
|
| 25 |
Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells
|
Paiva-Oliveira, Daniela I.
|
|
2017
|
81 |
1 |
p. 49-63
|
artikel
|
Tijdschrift beschrijving